Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnaris Launch Delayed While Altana Sniffs Out Marketing Partner

Executive Summary

Altana will need to secure a marketing agreement with an outside partner before introducing its newly approved allergic rhinitis treatment Omnaris (ciclesonide nasal spray), the company said

You may also be interested in...



Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs

Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.

Analysis Of Recent Drug Reviews Illuminates Path For Future NDAs

Every month, F-D-C Reports' Pharmaceutical Approvals Monthly dissects a new drug review by FDA. Using FDA's own review documents, including the discipline reviews, decision memos, meeting minutes, e-mails, and other documents, the publication strives to illuminate the agency decision-making process.

Altana Omnaris Adrenal Function Assessment Was “Not Ideal,” FDA Says

Study design deficiencies impeded Altana's attempt to distinguish Omnaris (ciclesonide) from other nasal corticosteroids as having less potential to suppress the cortisol system and adrenal function

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel